Literature DB >> 12719603

Induction of broad and potent anti-human immunodeficiency virus immune responses in rhesus macaques by priming with a DNA vaccine and boosting with protein-adsorbed polylactide coglycolide microparticles.

Gillis Otten1, Mary Schaefer, Catherine Greer, Maria Calderon-Cacia, Doris Coit, Jina Kazzaz, Angelica Medina-Selby, Mark Selby, Manmohan Singh, Mildred Ugozzoli, Jan zur Megede, Susan W Barnett, Derek O'Hagan, John Donnelly, Jeffrey Ulmer.   

Abstract

Several vaccine technologies were evaluated for their abilities to induce anti-human immunodeficiency virus Gag immune responses in rhesus macaques. While no vaccine alone was able to induce broad and strong immune responses, these were achieved by priming with Gag DNA and boosting with Gag protein adsorbed to polylactide coglycolide microparticles. This regimen elicited strong antibodies, helper T cells, and cytotoxic T lymphocytes and thus holds promise as an effective vaccination scheme.

Entities:  

Mesh:

Substances:

Year:  2003        PMID: 12719603      PMCID: PMC154004          DOI: 10.1128/jvi.77.10.6087-6092.2003

Source DB:  PubMed          Journal:  J Virol        ISSN: 0022-538X            Impact factor:   5.103


  40 in total

1.  DNA vaccination with the human immunodeficiency virus type 1 SF162DeltaV2 envelope elicits immune responses that offer partial protection from simian/human immunodeficiency virus infection to CD8(+) T-cell-depleted rhesus macaques.

Authors:  S Cherpelis; I Shrivastava; A Gettie; X Jin; D D Ho; S W Barnett; L Stamatatos
Journal:  J Virol       Date:  2001-02       Impact factor: 5.103

2.  Control of viremia and prevention of clinical AIDS in rhesus monkeys by cytokine-augmented DNA vaccination.

Authors:  D H Barouch; S Santra; J E Schmitz; M J Kuroda; T M Fu; W Wagner; M Bilska; A Craiu; X X Zheng; G R Krivulka; K Beaudry; M A Lifton; C E Nickerson; W L Trigona; K Punt; D C Freed; L Guan; S Dubey; D Casimiro; A Simon; M E Davies; M Chastain; T B Strom; R S Gelman; D C Montefiori; M G Lewis; E A Emini; J W Shiver; N L Letvin
Journal:  Science       Date:  2000-10-20       Impact factor: 47.728

3.  Protection from immunodeficiency virus challenges in rhesus macaques by multicomponent DNA immunization.

Authors:  J J Kim; J S Yang; L K Nottingham; D J Lee; M Lee; K H Manson; M S Wyand; J D Boyer; K E Ugen; D B Weiner
Journal:  Virology       Date:  2001-07-05       Impact factor: 3.616

4.  Rapid appearance of secondary immune responses and protection from acute CD4 depletion after a highly pathogenic immunodeficiency virus challenge in macaques vaccinated with a DNA prime/Sendai virus vector boost regimen.

Authors:  T Matano; M Kano; H Nakamura; A Takeda; Y Nagai
Journal:  J Virol       Date:  2001-12       Impact factor: 5.103

5.  ALVAC-SIV-gag-pol-env-based vaccination and macaque major histocompatibility complex class I (A*01) delay simian immunodeficiency virus SIVmac-induced immunodeficiency.

Authors:  R Pal; D Venzon; N L Letvin; S Santra; D C Montefiori; N R Miller; E Tryniszewska; M G Lewis; T C VanCott; V Hirsch; R Woodward; A Gibson; M Grace; E Dobratz; P D Markham; Z Hel; J Nacsa; M Klein; J Tartaglia; G Franchini
Journal:  J Virol       Date:  2002-01       Impact factor: 5.103

6.  Induction of neutralizing antibodies and gag-specific cellular immune responses to an R5 primary isolate of human immunodeficiency virus type 1 in rhesus macaques.

Authors:  D C Montefiori; J T Safrit; S L Lydy; A P Barry; M Bilska; H T Vo; M Klein; J Tartaglia; H L Robinson; B Rovinski
Journal:  J Virol       Date:  2001-07       Impact factor: 5.103

7.  HIV-1-specific cellular immune responses among HIV-1-resistant sex workers.

Authors:  K R Fowke; R Kaul; K L Rosenthal; J Oyugi; J Kimani; W J Rutherford; N J Nagelkerke; T B Ball; J J Bwayo; J N Simonsen; G M Shearer; F A Plummer
Journal:  Immunol Cell Biol       Date:  2000-12       Impact factor: 5.126

8.  Induction of potent immune responses by cationic microparticles with adsorbed human immunodeficiency virus DNA vaccines.

Authors:  D O'Hagan; M Singh; M Ugozzoli; C Wild; S Barnett; M Chen; M Schaefer; B Doe; G R Otten; J B Ulmer
Journal:  J Virol       Date:  2001-10       Impact factor: 5.103

9.  Reduction of simian-human immunodeficiency virus 89.6P viremia in rhesus monkeys by recombinant modified vaccinia virus Ankara vaccination.

Authors:  D H Barouch; S Santra; M J Kuroda; J E Schmitz; R Plishka; A Buckler-White; A E Gaitan; R Zin; J H Nam; L S Wyatt; M A Lifton; C E Nickerson; B Moss; D C Montefiori; V M Hirsch; N L Letvin
Journal:  J Virol       Date:  2001-06       Impact factor: 5.103

Review 10.  LTK63 and LTR72, two mucosal adjuvants ready for clinical trials.

Authors:  M Pizza; M M Giuliani; M R Fontana; G Douce; G Dougan; R Rappuoli
Journal:  Int J Med Microbiol       Date:  2000-10       Impact factor: 3.473

View more
  15 in total

1.  Enhanced potency of plasmid DNA microparticle human immunodeficiency virus vaccines in rhesus macaques by using a priming-boosting regimen with recombinant proteins.

Authors:  Gillis R Otten; Mary Schaefer; Barbara Doe; Hong Liu; Indresh Srivastava; Jan zur Megede; Jina Kazzaz; Ying Lian; Manmohan Singh; Mildred Ugozzoli; David Montefiori; Mark Lewis; David A Driver; Thomas Dubensky; John M Polo; John Donnelly; Derek T O'Hagan; Susan Barnett; Jeffrey B Ulmer
Journal:  J Virol       Date:  2005-07       Impact factor: 5.103

2.  Antibody-mediated protection against mucosal simian-human immunodeficiency virus challenge of macaques immunized with alphavirus replicon particles and boosted with trimeric envelope glycoprotein in MF59 adjuvant.

Authors:  Susan W Barnett; Brian Burke; Yide Sun; Elaine Kan; Harold Legg; Ying Lian; Kristen Bost; Fengmin Zhou; Amanda Goodsell; Jan Zur Megede; John Polo; John Donnelly; Jeffrey Ulmer; Gillis R Otten; Christopher J Miller; Michael Vajdy; Indresh K Srivastava
Journal:  J Virol       Date:  2010-04-14       Impact factor: 5.103

3.  Antigen expression kinetics and immune responses of mice immunized with noninfectious simian-human immunodeficiency virus DNA.

Authors:  Ramakrishna Hegde; ZhenQian Liu; Glenn Mackay; Marilyn Smith; Yahia Chebloune; Opendra Narayan; Dinesh K Singh
Journal:  J Virol       Date:  2005-12       Impact factor: 5.103

4.  A comparative analysis of HIV-specific mucosal/systemic T cell immunity and avidity following rDNA/rFPV and poxvirus-poxvirus prime boost immunisations.

Authors:  Charani Ranasinghe; Fiona Eyers; John Stambas; David B Boyle; Ian A Ramshaw; Alistair J Ramsay
Journal:  Vaccine       Date:  2011-02-23       Impact factor: 3.641

Review 5.  Engineering synthetic vaccines using cues from natural immunity.

Authors:  Darrell J Irvine; Melody A Swartz; Gregory L Szeto
Journal:  Nat Mater       Date:  2013-11       Impact factor: 43.841

6.  Biodegradable polylactide microspheres enhance specific immune response induced by Hepatitis B surface antigen.

Authors:  Shaohui Qiu; Qiang Wei; Zhenglun Liang; Guanghui Ma; Lianyan Wang; Wenqi An; Xiaowei Ma; Xin Fang; Peng He; Hemin Li; Zhongyu Hu
Journal:  Hum Vaccin Immunother       Date:  2014       Impact factor: 3.452

Review 7.  Non-human primate models for AIDS vaccine research.

Authors:  Shiu-Lok Hu
Journal:  Curr Drug Targets Infect Disord       Date:  2005-06

Review 8.  DNA vaccines against human immunodeficiency virus type 1 in the past decade.

Authors:  Malavika Giri; Kenneth E Ugen; David B Weiner
Journal:  Clin Microbiol Rev       Date:  2004-04       Impact factor: 26.132

9.  Preparation and characterization of innovative protein-coated poly(methylmethacrylate) core-shell nanoparticles for vaccine purposes.

Authors:  Rebecca Voltan; Arianna Castaldello; Egidio Brocca-Cofano; Giuseppe Altavilla; Antonella Caputo; Michele Laus; Katia Sparnacci; Barbara Ensoli; Silvia Spaccasassi; Marco Ballestri; Luisa Tondelli
Journal:  Pharm Res       Date:  2007-05-03       Impact factor: 4.200

Review 10.  Progress on new vaccine strategies against chronic viral infections.

Authors:  Jay A Berzofsky; Jeffrey D Ahlers; John Janik; John Morris; SangKon Oh; Masaki Terabe; Igor M Belyakov
Journal:  J Clin Invest       Date:  2004-08       Impact factor: 14.808

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.